Echosens™, founded in 2001, is a French high-technology company specialising in non-invasive diagnostics for use in hepatology. Echosens™ is very active in research and development, and currently holds patents from 17 different fields, focusing mainly on its key technology: Vibration-Controlled Transient Elastography (VCTE™). n innovative technology: Vibration-Controlled Transient Elastography (VCTE)
Echosens™ is the inventor of a highly innovative technology: pulse elastography. This has caused a fundamental change in the clinical practice of hepatologists. Echosens develops and markets the FibroScan®, a unique device for the diagnosis and monitoring of liver disease. The examination is non-invasive, fast, and painless. With more than 660 publications, FibroScan® with its dedicated probes is the elastography device with by far the most evidence to demonstrate its clinical usefulness.
The best-performing range of blood tests on the market
Applying the same philosophy, FibroMeter™ scores combine several biological markers to predict the presence of fibrosis in the liver. This complete range of blood scores, developed by Prof. Calès's team at the Angers teaching hospital in France, has given rise to the publication of many articles in world-class scientific journals, and is covered by a series of patents.
Echosens™ devotes a significant proportion of its activity to research, with the aim of developing new medical devices and opening up new medical horizons. The company works in close collaboration with health professionals and patients' associations to facilitate the therapeutic monitoring of patients.
To date, more than 2000 FibroScan® units have been installed all over the world.
Structure
Echosens™ is the inventor of a highly innovative technology: pulse elastography. This has caused a fundamental change in the clinical practice of hepatologists. Echosens develops and markets the FibroScan®, a unique device for the diagnosis and monitoring of liver disease. The examination is non-invasive, fast, and painless. With more than 660 publications, FibroScan® with its dedicated probes is the elastography device with by far the most evidence to demonstrate its clinical usefulness.
The best-performing range of blood tests on the market
Applying the same philosophy, FibroMeter™ scores combine several biological markers to predict the presence of fibrosis in the liver. This complete range of blood scores, developed by Prof. Calès's team at the Angers teaching hospital in France, has given rise to the publication of many articles in world-class scientific journals, and is covered by a series of patents.
Echosens™ devotes a significant proportion of its activity to research, with the aim of developing new medical devices and opening up new medical horizons. The company works in close collaboration with health professionals and patients' associations to facilitate the therapeutic monitoring of patients.
To date, more than 2000 FibroScan® units have been installed all over the world.
Structure
Location: France, Ile-de-France, Paris
Employees: 201-500
Phone: +33 1 44 82 78 50
Founded date: 2001
Investors 3
| Date | Name | Website |
| - | Cathay Cap... | cathaycapi... |
| - | Karista Ve... | karista.vc |
| - | Agoranov | agoranov.c... |
Mentions in press and media 4
| Date | Title | Description |
| 27.07.2024 | Calliditas Therapeutics: A Beacon of Hope in Rare Disease Treatment | In the ever-evolving landscape of biopharmaceuticals, Calliditas Therapeutics is making waves. The company recently announced significant advancements in two of its key treatments, setanaxib and Kinpeygo, which target rare diseases with sub... |
| 26.07.2024 | Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis | Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis Fri, Jul 26, 2024 08:00 CET Report this content Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced t... |
| 24.10.2022 | Echosens and ChronWell Announce Exclusive Strategic Partnership Between FibroScan and LIVErHEALTHY to Improve Patient Outcomes and Cost Savings | “NAFLD and NASH remain a silent and dangerous epidemic for over 80 million Americans. We are proud to partner with Echosens to offer healthcare providers and payers a scalable and cost-effective way to identify and treat those suffering fro... |
| - | Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring of Liver Disease | Jon Gingrich, CEO, Echosens North America Leveraging technological advances to facilitate new ways of engaging patients and integrating non-invasive technology into a liver disease program not only serves to improve individual outcomes and ... |